Mirae Asset Global Etfs Holdings Ltd. Prelude Therapeutics Inc Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 8,135 shares of PRLD stock, worth $19,849. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,135Holding current value
$19,849% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PRLD
# of Institutions
62Shares Held
33.9MCall Options Held
400Put Options Held
100-
Orbimed Advisors LLC San Diego, CA10.9MShares$26.6 Million1.0% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$24.7 Million0.51% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.13MShares$10.1 Million0.33% of portfolio
-
Boxer Capital, LLC San Diego, CA2.57MShares$6.27 Million0.54% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$2.61 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $88.7M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...